E-mail ID : info@iamg.in |
Online Submission |
Click Here For Online Submission |
Instructions for authors |
Genetic Clinics |
Editorial board |
Get Our Newsletter |
Subscribe |
Send Your Feedback |
Feedback Form |
About Us |
IAMG |
Abstract
April-June 2017 | Vol. 10 | Issue 2 | Page No 20-21 | |||
Myth Unmethylated: Novel Therapies for Methylation-Related Neurodevelopmental Disorders | |||
Shivani Mishra | |||
Department of Medical Genetics, Sanjay Gandhi Post graduate Institute of Medical Sciences, Lucknow, India | |||
Address for Correspondence Email: drshivani2005@gmail.com | |||
Abstract Fragile X syndrome (FXS) is a CGG-repeat disorder of the FMR1 gene caused by epigenetic gene silencing. In the presence of the elongated CGG repeat, epigenetic modifying drugs result in only transient FMR1 reactivation. CRISPR/Cas9 genome editing was used to excise the expanded CGG-repeat in both somatic cell hybrids containing the human fragile X chromosome and human FXS iPS cells. Transcriptional reactivation was observed in approximately 67% of the CRISPR cut hybrid colonies and in 20% of isolated human FXS iPSC colonies. The reactivated cells produced fragile X mental retardation protein (FMRP) and exhibited a decrease in DNA methylation at the FMR1 locus. | |||
HTML Full Text | Download PDF |